HC Wainwright Issues Positive Forecast for Microbot Medical (NASDAQ:MBOT) Stock Price

Microbot Medical (NASDAQ:MBOT) had its price objective raised by investment analysts at HC Wainwright from $7.00 to $9.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 371.20% from the stock’s previous close.

Microbot Medical Stock Performance

MBOT stock opened at $1.91 on Friday. The firm has a market cap of $38.66 million, a PE ratio of -2.39 and a beta of 1.46. The firm’s 50 day moving average price is $1.27 and its 200-day moving average price is $1.07. Microbot Medical has a one year low of $0.82 and a one year high of $3.38.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.